Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...

A paper inadvertently published on the website of an ASCO conference revealed good results for mevrometostat in treating ...

Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. | ...

Pfizer (PFE) reported positive results from a Phase 3 study of Talzenna in combination with Xtandi in the treatment of ...

Food and drug companies have expressed optimism, but the new health secretary and his MAHA movement will likely make waves.

All this negativity, however, does open up an opportunity for investors to buy the stock at a discount. Despite being a top ...

The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval ...

Hims & Hers' “Sick of the System” spot not only generated the highest engagement of all pharma-related ads that aired during ...

Pfizer’s contributions to animal health date back several decades, during which the company played a significant role in ...

Corbus Pharmaceuticals has posted the first Western clinical data on its would-be rival to Pfizer’s Padcev. The overall ...

Leaked data showed that Pfizer’s mevrometostat has strong therapeutic potential in metastatic castration-resistant prostate ...

The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...